Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor

Mise à jour : Il y a 4 ans
Référence : NCT00137449

Femme et Homme

Extrait

To evaluate the antitumor activity of SU011248 in advanced, imatinib mesylate-resistant gastrointestinal stromal tumor (GIST) when administered on a continuous daily dosing schedule


Critère d'inclusion

  • gastrointestinal stromal tumors

Liens